These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 33601389)
21. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K; Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results. Elbarky AM Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902 [TBL] [Abstract][Full Text] [Related]
24. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Zur D; Iglicki M; Busch C; Invernizzi A; Mariussi M; Loewenstein A; Ophthalmology; 2018 Feb; 125(2):267-275. PubMed ID: 28935399 [TBL] [Abstract][Full Text] [Related]
25. The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus. Kolomeyer AM; Eichenbaum DA; Kiernan DF; Suñer IJ; Hariprasad SM Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):166-173. PubMed ID: 36944067 [TBL] [Abstract][Full Text] [Related]
26. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051 [TBL] [Abstract][Full Text] [Related]
27. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376 [TBL] [Abstract][Full Text] [Related]
29. Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study. Riemann CD; Eaton AM; Cutino A Ophthalmic Surg Lasers Imaging Retina; 2020 May; 51(5):298-306. PubMed ID: 32511735 [TBL] [Abstract][Full Text] [Related]
37. Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. Holden SE; Currie CJ; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):45-52. PubMed ID: 28881146 [TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study. Cutino A; Green K; Kendall R; Moore PT; Zachary C Am J Manag Care; 2015 Jan; 21(4 Suppl):S63-72. PubMed ID: 25734663 [TBL] [Abstract][Full Text] [Related]
39. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F; Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data. Avogaro F; Florido A; Calandri A; Toja F; Vingolo EM Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):1759-1766. PubMed ID: 36930491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]